目的 探討組蛋白修飾與胃腸道惡性腫瘤的關(guān)系。
方法 復(fù)習(xí)組蛋白修飾以及組蛋白修飾與胃腸道惡性腫瘤之間關(guān)系的相關(guān)文獻(xiàn)并進(jìn)行綜述。
結(jié)果 組蛋白的修飾為表遺傳改變之一,能導(dǎo)致基因表達(dá)的改變,在惡性腫瘤的發(fā)生、發(fā)展中起重要作用。DNA甲基化與組蛋白修飾間相互作用,形成復(fù)雜系統(tǒng),維持基因沉默。表觀遺傳修飾具有可逆性,逆轉(zhuǎn)表觀遺傳修飾,從而改變基因表達(dá)狀態(tài),可能使惡性腫瘤細(xì)胞正?;ǚQ為表觀基因治療)。表觀基因治療對于胃腸道惡性腫瘤的預(yù)防和治療具有廣闊的應(yīng)用前景,但還有許多問題需進(jìn)一步研究證實(shí)。
結(jié)論 組蛋白修飾與胃腸道惡性腫瘤的發(fā)生有關(guān),逆轉(zhuǎn)表觀遺傳修飾導(dǎo)致的基因表達(dá)改變對于胃腸道惡性腫瘤的預(yù)防和治療具有重要意義。
引用本文: 孟春風(fēng),戴冬秋. 組蛋白修飾與胃腸道惡性腫瘤的關(guān)系. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(5): 608-611. doi: 復(fù)制
1. | Wolffe AP, Matzke MA. Epigenetics: regulation through repression [J]. Science, 1999; 286(5439)∶481. |
2. | Feinberg AP, Vogelstein B. Hypomethylation distinguishes ge-nes of some human cancers from their normal counterparts [J]. Nature, 1983; 301(5895)∶89. |
3. | Strahl BD, Allis CD. The language of covalent histone modifications [J]. Nature, 2000; 403(6765)∶41. |
4. | 楊少輝, 戴冬秋. 腫瘤抑制基因甲基化與胃癌 [J]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(5)∶614. |
5. | Rea S, Eisenhaber F, O’Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases [J]. Nature, 2000; 406(6796)∶593. |
6. | Jenuwein T, Allis CD. Translating the histone code [J]. Science, 2001; 293(5532)∶1074. |
7. | Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase [J]. Mol Cell, 2001; 8(6)∶1207. |
8. | Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote [J]. Genes Dev, 2004; 18(11)∶1263. |
9. | Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome [J]. Proc Natl Acad Sci USA, 2004; 101(19)∶7357. |
10. | Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 [J]. Cell, 2004; 119(7)∶941. |
11. | Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 ph-osphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors [J]. Cell, 1991; 65(5)∶775. |
12. | Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation [J]. Trends Genet, 2004; 20(4)∶214. |
13. | Salvador LM, Park Y, Cottom J, et al. Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells [J]. J Biol Chem, 2001; 276(43)∶40146. |
14. | Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications [J]. Cell, 2000; 103(2)∶263. |
15. | Nowak SJ, Corces VG. Phosphorylation of histone H3 correlates with transcriptionally active loci [J]. Genes Dev, 2000; 14(23)∶3003. |
16. | Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J]. Nat Genet, 1999; 21(1)∶103. |
17. | Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer [J]. Mol Cell Biol, 2003; 23(1)∶206. |
18. | Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer [J]. Cancer Res, 2002; 62(24)∶7213. |
19. | Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation [J]. J Biol Chem, 2003; 278(6)∶4035. |
20. | Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J]. Cancer Cell, 2003; 3(1)∶89. |
21. | Cheung P, Tanner KG, Cheung WL, et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation [J]. Mol Cell, 2000; 5(6)∶905. |
22. | Lo WS, Trievel RC, Rojas JR, et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 [J]. Mol Cell, 2000; 5(6)∶917. |
23. | Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails [J]. Genes Dev, 2001; 15(18)∶2343. |
24. | Wang H, Huang ZQ, Xia L, et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor [J]. Science, 2001; 293(5531)∶853. |
25. | Fang JY, Chen YX, Lu J, et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116 [J]. Cell Res, 2004; 14(3)∶217. |
26. | Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma [J]. J Pathol, 2005; 205(1)∶65. |
27. | Hamai Y, Oue N, Mitani Y, et al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma [J]. Cancer Sci, 2003; 94(8)∶692. |
28. | Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines [J]. Oncol Res, 2005; 15(1)∶39. |
29. | Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature, 2004; 429(6990)∶457. |
30. | Dobosy JR, Roberts JL, Fu VX, et al. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia [J]. J Urol, 2007; 177(3)∶822. |
31. | Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes [J]. Clin Cancer Res, 2005; 11(10)∶3604. |
- 1. Wolffe AP, Matzke MA. Epigenetics: regulation through repression [J]. Science, 1999; 286(5439)∶481.
- 2. Feinberg AP, Vogelstein B. Hypomethylation distinguishes ge-nes of some human cancers from their normal counterparts [J]. Nature, 1983; 301(5895)∶89.
- 3. Strahl BD, Allis CD. The language of covalent histone modifications [J]. Nature, 2000; 403(6765)∶41.
- 4. 楊少輝, 戴冬秋. 腫瘤抑制基因甲基化與胃癌 [J]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(5)∶614.
- 5. Rea S, Eisenhaber F, O’Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases [J]. Nature, 2000; 406(6796)∶593.
- 6. Jenuwein T, Allis CD. Translating the histone code [J]. Science, 2001; 293(5532)∶1074.
- 7. Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase [J]. Mol Cell, 2001; 8(6)∶1207.
- 8. Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote [J]. Genes Dev, 2004; 18(11)∶1263.
- 9. Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome [J]. Proc Natl Acad Sci USA, 2004; 101(19)∶7357.
- 10. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 [J]. Cell, 2004; 119(7)∶941.
- 11. Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 ph-osphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors [J]. Cell, 1991; 65(5)∶775.
- 12. Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation [J]. Trends Genet, 2004; 20(4)∶214.
- 13. Salvador LM, Park Y, Cottom J, et al. Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells [J]. J Biol Chem, 2001; 276(43)∶40146.
- 14. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications [J]. Cell, 2000; 103(2)∶263.
- 15. Nowak SJ, Corces VG. Phosphorylation of histone H3 correlates with transcriptionally active loci [J]. Genes Dev, 2000; 14(23)∶3003.
- 16. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J]. Nat Genet, 1999; 21(1)∶103.
- 17. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer [J]. Mol Cell Biol, 2003; 23(1)∶206.
- 18. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer [J]. Cancer Res, 2002; 62(24)∶7213.
- 19. Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation [J]. J Biol Chem, 2003; 278(6)∶4035.
- 20. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J]. Cancer Cell, 2003; 3(1)∶89.
- 21. Cheung P, Tanner KG, Cheung WL, et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation [J]. Mol Cell, 2000; 5(6)∶905.
- 22. Lo WS, Trievel RC, Rojas JR, et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 [J]. Mol Cell, 2000; 5(6)∶917.
- 23. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails [J]. Genes Dev, 2001; 15(18)∶2343.
- 24. Wang H, Huang ZQ, Xia L, et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor [J]. Science, 2001; 293(5531)∶853.
- 25. Fang JY, Chen YX, Lu J, et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116 [J]. Cell Res, 2004; 14(3)∶217.
- 26. Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma [J]. J Pathol, 2005; 205(1)∶65.
- 27. Hamai Y, Oue N, Mitani Y, et al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma [J]. Cancer Sci, 2003; 94(8)∶692.
- 28. Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines [J]. Oncol Res, 2005; 15(1)∶39.
- 29. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature, 2004; 429(6990)∶457.
- 30. Dobosy JR, Roberts JL, Fu VX, et al. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia [J]. J Urol, 2007; 177(3)∶822.
- 31. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes [J]. Clin Cancer Res, 2005; 11(10)∶3604.